Chemoresistance to many commercially available cancer therapeutic drugs is a common occurrence and contributes to cancer mortality as it often leads to disease progression. There have been a number of studies evaluating the mechanisms of resistance and the biological factors involved. microRNAs have recently been identified as playing a role in the regulation of key genes implicated as cancer therapeutic targets or in mechanisms of chemoresistance including: EGFR, MDR1, PTEN, Bak1, and PDCD4, among others. This paper briefly reviews chemoresistance mechanisms, discusses how microRNAs can play a role in those mechanisms, and summarizes current research involving microRNAs as both regulators of key target genes for chemoresistance and biomarkers for treatment response. It is clear from the accumulating literature that microRNAs can play an important role in chemoresistance and hold much promise for the development of targeted therapies and personalized medicine. This review brings together much of this new research as a starting point for identifying key areas of interest and potentials for future study. 
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Copyright © 2010 American Association for Cancer Research cancer cells (5) . Three proteins commonly known for their role in classical MDR are Pglycoprotein (P-gp; from MDR1 and ABCB1 genes), MDR-associated protein (MRP1; from ABCC1 gene), and breast cancer resistant protein (BCRP; from ABCG2 gene) (5) . All three of these proteins contain hydrophobic compounds that are similar in their chemistry, and thus overlap in the substrate specificities that facilitate drug transport across the cell membrane (5) .
In addition to the above mechanisms for MDR, there are clinical studies that connect expression or polymorphisms of certain genes with response to chemotherapy drugs. These include (i) high expression of the MDR1 and ERCC1 genes in association with reduced response to cisplatin therapy in advanced bladder cancer (9) ; (ii) high expression of ERCC1, LRP, and MRP1 genes in NSCLC patients predicting response to cisplatin-based therapies (10); (iii) EGFR,
ERCC1,MDR1, XRCC1, XRCC3, XPA, and XPD gene polymorphisms as predictive biomarkers
for treatment response to EGFR kinase inhibitors and platinum-based therapies in NSCLC patients (11) , (12) ; (iv) low levels of dehydropyrimidine dehydrogenase (DPD) and thymidylate synthase (TS) mRNA expression in colorectal and gastric cancers predicting sensitivity to 5-FU (13) , (14) ; (v) genotyping of CYP2D6 in breast cancer patients to identify those most likely to respond well to adjuvant tamoxifen therapy (15) . Thus, there are a number of mechanisms for drug resistance. In all cases, discovering ways to better define drug resistance is the first step towards designing methods to circumvent resistance and offer more viable treatment options for patients. 
microRNAs Defined and Their Involvement in Chemoresistance
To date there are a number of research findings, both laboratory and clinic based, that have reported the implications of microRNAs (miRNAs) in chemoresistance. While their involvement is apparent, the study of the specific pathways they are involved in and the mechanisms they help regulate is just beginning.
miRNAs are short (~22 nucleotide), non-protein-coding RNAs that are known to alter gene expression at a post-transcriptional level (16, 17) . Over 1,200 validated human miRNAs have been identified to date (www.mirbase.org), and they are predicted to regulate one third of the human genome with involvement in development and progression of many diseases (18) (19) (20) .
Recent studies have uncovered broad implications of miRNAs, demonstrating that a single miRNA can impact hundreds of targets (21) and also that a single target can be affected by multiple miRNAs (22) . The result is that miRNAs can affect many cellular pathways; most notably those pathways controlling developmental and oncogenic processes (23, 24) . Close to half of the genes known to be regulated by miRNAs are located in cancer-associated genomic regions, or fragile genomic sites (25) . Additionally, mutation or aberrant expression of many miRNAs has been found in cancer patients-leading to the study of miRNAs as regulators of oncogenes and tumor suppressor genes (26, 27) . Defects in miRNA processing have also been shown to enhance tumorigenesis (28) , supporting the hypothesis that miRNAs may truly be posttranscriptional regulators of oncogenes. The Era of Targeted Therapy-promise, resistance, and microRNAs that may bridge the gap Research over the past several years has narrowed the focus of targeted therapy to the specific biological condition of a patient's tumor that provides the optimum treatment for that tumor's individual genetic profile. With equal interest, specific pathways have been studied to determine if/how they integrate into the era of targeted treatments and personalized medicine. Although targeted treatment has improved the benefit to the patient, resistance to therapy still ultimately develops in most patients (5) . In response to the need to overcome this resistance to chemotherapy drugs, much new research is focused on mechanisms of resistance, and ways to circumvent it. This section will lay the groundwork for the involvement of miRNAs in the chemoresistance story by looking at a few of the target genes and relevant pathways that are known to be involved in predicting patients at risk for resistance to certain chemotherapy drugs, and that are also suspected targets of specific miRNAs.
Genes affected by a miRNA pathway are often involved in cellular response to cancer drugs (6), including changes in drug transport, apoptosis, and cell death. Specific examples of miRNAs implicated in chemoresistance are discussed below. The findings in all of these examples are the beginning to a vast field of possibilities that require further clinical validation, using miRNAs first as biomarkers to predict drug resistance in order to better direct patient treatment, and second as possible drug targets to reverse resistance once it has developed in a tumor. As enumerated in Table 1 
microRNAs as Biomarkers for Chemoresistance
As the medical field has become accustomed to specific genes pointing the way to the most useful therapy, or directing the discovery of new therapies, miRNAs are also growing in the same application. The discovery of biological molecules-biomarkers-as determinants for optimal treatment course, treatment outcome, and reduction of healthcare costs (by only offering treatments if they are shown to be efficacious), is a growing area of interest in the medical research field [see detailed review on this topic in (31)]. miRNAs have thus far shown much promise as credible biomarkers that are relatively easy to collect and measure (32) , and current research has been building to support the hypothesis that over-or under-expression of a certain miRNA can be directly tied to a patient's response to chemotherapeutic agents. These short nucleotide strands are more stable than mRNA and even some proteins, and can thus be measured from formalin-fixed paraffin-embedded (FFPE) samples and bodily fluids (e.g. blood and sputum samples), the latter allowing for less invasive sample acquisition and analysis (32) .
miRNAs circulating in the body are also expected to provide higher levels of specificity and sensitivity over other presently measured biomarkers (32) . Discussed below are some of the current findings that relate miRNA expression levels and their implications in chemoresistance. Further validation of these miRNAs is warranted, and in some cases is currently in progress, to verify these miRNAs as biomarkers that confirm resistance in lung cancer treatment.
In two studies by Song et al., miR-140 and -215 were found to be over-expressed in drug resistant colorectal cancer cell lines (34, 35) . Based on their findings, these miRNAs correlated with resistance to the anticancer drugs methotrexate, 5-fluorouacil, and tomudex. Additionaly, an analysis of possible protein targets for these miRNAs pointed to HDAC4 and DHFR;
respectively (34, 35) .
Ovarian cancer is also increasing its portfolio of miRNAs implicated as chemoresistance biomarkers. miRNAs that have been found to date to confer resistance when aberrantly expressed in ovarian cancer include miR-30c, -130a, -335 (36), -214, and let-7i (2). Further, miR-30c, -130a, and -335 have been shown to have an effect on M-CSF (36), while miR-214 has been shown to affect PTEN (2) . PTEN is a known tumor suppressor gene, and downregulation of PTEN can thus lead to unchecked cell growth (discussed in more detail in the following section of this manuscript).
As the examples above show, the field of miRNAs as predictors for chemoresistance is burgeoning. There are additional miRNAs implicated as chemoresistance biomarkers reported in other cancers including pancreatic, gastric, cervical, ALL, prostate, and others. See Table 1 Some preliminary studies in NSCLC cell lines, exploring miRNA biomarkers associated with TKI resistance in vitro, reported that increased levels of both miR-21 and miR-23b were indicative of increased sunitinib resistance in NSCLC cell lines (42, 43) while decreased miR-424 levels were indicative of increased resistance to both erlotinib and vandetanib (42) . As with most of these newly discovered biomarkers, more research is currently under way to validate these miRNAs, translate the findings to an in vivo study, and explore ways to apply any validated findings as legitimate tools for predicting treatment response.
MDR1 and miR-451
Activation of the MDR1/ABCB1 gene is a commonly known pathway for chemoresistance, and results in the overexpression of P-gp, a multidrug transporter glycoprotein that belongs to the ATP-binding cassette super family (7) . When P-gp is overexpressed in cells, they become resistant to a variety of structurally and functionally diverse chemotherapy drugs (7).
In a study of MCF-7/DOX, doxorubicin-resistant breast cancer cells, miR-451 was found to be decreased in expression in the resistant cell line compared with control cells that were not doxorubicin-resistant (44) . Further, the study demonstrated that miR-451 regulates the MDR1 gene. Increasing the cellular levels of miR-451 decreased MDR1 expression, and more importantly, increased cell sensitivity to doxorubicin (44) . This resulted in reversal of doxorubicin resistance observed in the presence of MDR1 expression and helped to circumvent the MDR1 resistance pathway. Another suppressor mechanism for PTEN, leading to tamoxifen resistance in breast cancer, has been discovered through Magi-2, a scaffold protein that activates PTEN through phosphorylation (47). Tamoxifen is a widely known anti-cancer drug used in treatment of breast cancer. An estrogen antagonist that vies with estrogen for binding at estrogen receptor (ER) sites, it inhibits gene transcription and tumor growth that is dependent on estrogen. Resistance to this form of therapy is often seen in tumor cells that become estrogen independent, and are thus also uninhibited by tamoxifen (48). Two preliminary studies recently identified miRNAs that seem to be involved in tamoxifen resistance. The first study examined the role miRNAs play in estrogen independent growth of breast cancer cells. The authors report that miR-101 transfected into MCF-7 cells was able to promote estrogen independent growth, which also led to tamoxifen 
Bak1 and miR-125b
Another common drug used to treat breast (and other) cancers is paclitaxel. Zhou et al. recently 
miR-21-more to the story?
As noted in Table 1 
Future Directions
The field of study with miRNAs is vast and has many areas of application. A single miRNA can regulate tens to hundreds of gene targets, and it is essential that this library of information continues to be built up for further investigation of miRNA effects on resistance mechanisms, and potential ways to reverse or alter these effects. If additional studies continue to validate specific miRNAs as biomarkers for chemoresistance, they will enable the scientific community to advance patient care through improved stratification for clinical trials (leading to new drug treatments), and through increased development of targeted treatments much the way genes have.
Current cancer treatments are selected by evidence from clinical trials directed at specific cancer populations as well as patient/physician convenience for known toxicity. While there are currently several methods (discussed earlier) used to identify patients who may be at risk for resistance, there exist few standardized reliable methods to identify cancers that may be resistant to the selected course of systemic therapy. It is imperative that the scientific community pursue research avenues to both predict and overcome chemoresistance, in order to improve treatment options and outcomes for patients.
There is particular promise for the future in targeting miRNAs as therapeutics to guide personalized medicine. One potential use for miRNAs is to serve as predictive biomarkers to direct therapies that are currently available on the market, and thus improve treatment response and outcomes. They also hold promise in the field of drug development to give direction for new therapies that are currently emerging on the research front, particularly for therapeutic development as miRNA mimics or antagomirs. The critical step to developing miRNAs for human use is to create stable and effective targeted delivery with minimization of other potential and probable target and off-target effects. A phase II study is currently underway (www.clinicaltrials.gov, study #NCT01200420). The study tests a proprietary nucleic acid (miraversen) that captures miR-122, a miRNA important for hepatitis C viral replication. Originally tested in chimpanzees, the molecule has so far shown to be effective with no evidence of resistance or side effects in the treated animals. Miraversen is the first miRNA-targeted drug therapy to go into human clinical trials. The study is expected to be completed in December 2011 and could lead to the beginning of an exciting and rapidly expanding aspect of miRNA targets as therapeutics for personalized medicine.
In summary, miRNAs hold promise as biomarkers for chemoresistance that will help guide patient treatments for optimum results with minimum toxicity to the patient, as well as for the development of therapeutic treatments that precisely and directly target the biological area of interest-the developing field of personalized medicine. 
